RecruitingNCT07400926
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg
Sponsor
Glaukos Corporation
Enrollment
30 participants
Start Date
Dec 17, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Diagnosis of Open-angle glaucoma
- years of age or older
Exclusion Criteria1
- Subject who is breast-feeding or pregnant
Interventions
COMBINATION_PRODUCTTravoprost
Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07400926
Related Trials
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
NCT072902442 locations
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
NCT073544771 location
iStent Inject Versus Goniotomy With Kahook Dual Blade in Glauocma Treatment
NCT073255522 locations
Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT069640613 locations
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
NCT0722087612 locations